SynthesisThe breast journal2026
Efficacy and Tolerability of Methotrexate for Idiopathic Granulomatous Mastitis: A Systematic Review and Meta-Analysis.
Synthesis in The breast journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Efficacy and Tolerability of Methotrexate for Idiopathic Granulomatous Mastitis: A Systematic Review and Meta-Analysis.The breast journal · 2026Pooled it
- Therapeutic strategies for idiopathic granulomatous mastitis: an umbrella review of systematic reviews and meta-analyses.Frontiers in medicine · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Idiopathic granulomatous mastitis (IGM) is a challenging inflammatory breast disease with limited standardized treatment guidelines. Methods: This meta-analysis systematically evaluated the efficacy and safety of methotrexate (MTX) in IGM, pooling data from observational studies. We assessed complete remission rates, recurrence rates, and severe side effects leading to MTX discontinuation using both common and random effects models, accounting for heterogeneity. Results: Nine studies were included. In analyses without control groups, the pooled complete response rate for MTX was 61.6% (95% CI: 40.4-79.2%), with significant heterogeneity ( Conclusion: Based on a pooled complete response rate of 61.6%, MTX appears to be an effective and well-tolerated treatment for IGM, though substantial heterogeneity exists in uncontrolled studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.